• OCT 26 2017

    ONC201 Biomarkers and Pharmacology at ENA Conference October 27-29th in Philadelphia

    Three abstracts involving Oncoceutics’ lead clinical compound, ONC201, will be presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia on October 28th and 29th, 2017. ONC201 is the first Dopamine Receptor 2 (DRD2) antagonist for clinic oncology and the first imipridone to enter the clinic, with 8 active clinical trials

    • SEP 25 2017

    Oncoceutics to Present Imipridone Class at Discovery On Target Conference

    At the upcoming Cambridge Healthtech Institute’s 12th Annual GPCR-Based Drug Discovery conference, September 26th and 27th in Boston, Oncoceutics will be presenting data on the company’s lead imipridone ONC201, and other members of the imipridone class. On September 26th at 11:55am, Dr. Varun Prabhu will present “Imipridones: A New Class of Anti-Cancer Small Molecules that Selectively Engage GPCRs.”

    • MAY 26 2017

    Dr. Joshua Allen to Present Results of ONC201 in Recurrent GBM at the 2017 Brain Tumor Biotech Summit

    Dr. Joshua Allen, VP of Research and Development at Oncoceutics, will present a talk titled “Activity of the Selective DRD2 Antagonist ONC201 in Recurrent Glioblastoma” at the Brain Tumor Biotech Summit 2017 at Lenox Hill Hospital in New York on June 2nd. The full agenda can be found here.

    • MAY 18 2017

    ONC201 Abstracts to be Presented at ASCO 2017

    Abstracts describing the recent clinical experience of ONC201 across various solid tumors will be presented at the 2017 American Society of Clinical Oncology (ASCO) annual meeting. The first, “Clinical activity of the selective DRD2 antagonist ONC201, an imipridone, in metastatic endometrial cancer (mEC)” will be presented in the session Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics